IPC - Global registry-based study reveals biologics use is associated with lower risk of COVID-19-related hospitalizations

Global registry-based study reveals biologics use is associated with lower risk of COVID-19-related hospitalizations

According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies.

Read the full article here:

Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study

Categories: COVID-19, IPC News, Blog

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

Search Our Blog

Advancing Knowledge. Enhancing Care.

Support Our Work

IPC's mission is to advance the care of people with psoriasis worldwide, through education, research and advocacy.

IPC is not in any way engaged in the practice of medicine or acting as a physician or health care professional or provider. The information IPC publishes is not intended as a substitute for the exercise of professional medical judgement by a health care provider following examination of a patient's condition. The ultimate responsibility for a patient's diagnosis or medical treatment rests with the patient's health care provider.